Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance

Abbott LaboratoriesTrade
Schwab US Dividend Equity ETFTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Schwab US Dividend Equity ETF — how do they compare? Abbott Laboratories trades at $109.69 (market cap $187.95B), while Schwab US Dividend Equity ETF trades at $34.32. The key difference: Abbott Laboratories pays a 2.32% dividend while Schwab US Dividend Equity ETF pays none, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.

ABTSCHD
Market Cap
$187.95B
Sector
HealthBroad Market / Factor
52-Week High
$136.62$34.27
52-Week Low
$82.57$26.44
Enterprise Value
$214.96B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

Schwab US Dividend Equity ETF

SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.

The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Schwab US Dividend Equity ETF

SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.

Read more on SCHD